Normal
cell
cell
Genetic instability is a hallmark of cancer resulting in the accumulation of mutations. These mutations can directly alter the function on genes to confer a growth or survival advantage to the cancer cell or force the cancer cell to adapt the function of other genes to survive. This in turn can lead the cell to become dependent on specific proteins or pathways for survival, exposing exploitable vulnerabilities that can be targeted with a precision medicine to provide benefit to biomarker selected patients.
At Dark Blue Therapeutics we are committed to delivering medicines that transform the outcomes for cancer patients. We work across a variety of biological mechanisms to identify and pursue only cancer targets that have the highest transformative potential. This is coupled with cutting-edge target validation, translational medicine and discovery science to deliver drugs with mechanisms of action carefully tuned to provide maximal impact against individual targets.
Dark Blue Therapeutics is developing first-in-class small molecule inhibitors of the transcriptional regulator, MLLT 1/3, for use as monotherapy and as the backbone for combination therapy in patients with acute myeloid leukemia (AML) and solid cancers.
Dark Blue Therapeutics is developing first-in-class small molecule inhibitors of the RNA editing enzyme, ADAR1, for use as monotherapy and as combination therapy in patients with solid cancers including prostate, liver and colorectal cancer.
Dark Blue Therapeutics is developing novel small molecule inhibitors of SMO (Smoothened) for use as monotherapy in patients with solid cancers including basal cell carcinoma, pancreatic and esophageal cancer.
